A Phase 1/2 interventional study of cardiac surgery requiring ECC in Bleeding, sponsored by AdministrateurCIC. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-20.
Sponsored by AdministrateurCIC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Hemorrhage with a site in France — 25 open to participants now, 31 under way, 4 of them phase 3. Hemorrhage · France.
Among the 120 studies in Hemorrhage with a site in France, this one is the 63rd largest by enrollment of the 74 interventional ones that give a count, is one of 7 that started in 2009, is one of 2 in phase 1/2, and was the 14th registered.
1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.
Browse Hemorrhage studies →25 of the 120 studies in Hemorrhage with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Annecy Genevois · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
Takeda · Sites in France, United States, Australia and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 13 · Phase 3 19 · Phase 4 8
First in 2003; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 102 across 927 interventional studies indexed under Hemorrhage.
Median enrollment 150 across the 74 interventional studies, 222 across the 46 observational. Of the 78 that completed or were terminated, 6 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 120 have an industry lead sponsor. The 10 most frequent:
AdministrateurCIC is the lead sponsor of 8 studies on the registry; none are open to participants now.
AdministrateurCIC has 1 study filed under Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies in Hemorrhage with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05198960Phase 3University Hospital, BrestAVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms | 2027-07-13 |
| NCT07259135University Hospital, BordeauxLink Between Abnormal Bleeding and Coagulation Disorders in Noonan Syndromes | 2027-01 |
| NCT06425614University Hospital, BordeauxCOmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial | 2027-02-15 |
| NCT06749405University Hospital, ToulouseAssessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 120 studies in Hemorrhage with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
the purpose of this study is to show that the vacuum control surgical bleeding helps stop bleeding extraMD (MD: Medical Device) at the orifice of the retrograde cannulation during a heart with Extra-corporeal circulation (ECC),
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: cardiac surgery requiring ECC
the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
Persistence or absence of bleeding extraMD at the orifice of the retrograde cannulation when the suction cup is in place.
Time frame: 20-30 min
Persistence or absence of bleeding intraMD at the orifice of the retrograde cannulation when the suction cup is in place.
Time frame: 20-30 min
Persistence or absence of bleeding at the orifice of the retrograde cannulation when the vacuum was removed.
Time frame: 20-30 min
Persistence or absence of bleeding extraMD at the orifice of the aortic purge when the suction cup is in place.
Time frame: 20- 30 min
Persistence or absence of bleeding extraMD at the orifice of the aortic purge when the suction cup is in place.
Time frame: 20 -30 min
Persistence or absence of bleeding at the orifice of the aortic purge when the vacuum was removed.
Time frame: 20 -30 min
The record gives a start of Oct 2009, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AdministrateurCIC